Annex: UK Five Year Antimicrobial Resistance
Strategy 2013-2018: outline of the responsibilities of pharmaceutical
companies
Pharmaceutical Industry
5.6 Industry has a corporate and social responsibility
to contribute to work to tackle AMR by finding ways of extending
the life of antibiotics, making the supply of effective antibiotics
sustainable, facilitating society in being better custodians of
these valuable resources and using them optimally both now and
the future.
5.7 Pharmaceutical, bio-pharmaceutical and diagnostics
manufacturers and trade associations need to stimulate the development
of new antibiotics, rapid diagnostics and novel therapies by:
· improving
collaborative working to ensure excellent science is developed
and has a clear route for translation,
· developing
a European product development partnership scheme for antimicrobial
drugs,
· developing
new treatments for all infections, particularly bacterial, from
rigorous identification of new targets through to new paradigms
for treatment,
· utilising
the 'Innovative Medicines Initiative' (IMI), which may facilitate
stimulating the development of new antibiotics, rapid diagnostics
and novel therapies,
· developing
new vaccines targeted at multi-resistant organisms,
· increasing
involvement in genomic diagnostics and the improvement of companion
diagnostics for drug development in this field.
| 
